Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains

被引：0
|
作者：
机构：
[1] [1,Hay, Duncan A.
[2] 2,Fedorov, Oleg
[3] 2,Martin, Sarah
[4] 2,Singleton, Dean C.
[5] 2,Tallant, Cynthia
[6] 2,Wells, Christopher
[7] Picaud, Sarah
[8] 2,Philpott, Martin
[9] 2,Monteiro, Octovia P.
[10] 2,Rogers, Catherine M.
[11] Conway, Stuart J.
[12] Rooney, Timothy P. C.
[13] 2,Tumber, Anthony
[14] 2,Yapp, Clarence
[15] Filippakopoulos, Panagis
[16] Bunnage, Mark E.
[17] 2,Müller, Susanne
[18] 2,Knapp, Stefan
[19] Schofield, Christopher J.
[20] 2,Brennan, Paul E.
来源：
Brennan, P.E. (paul.brennan@sgc.ox.ac.uk) | 1600年 / American Chemical Society卷 / 136期
关键词：
Small-molecule inhibitors that target bromodomains outside of the bromodomain and extra-terminal (BET) sub-family are lacking. Here; we describe highly potent and selective ligands for the bromodomain module of the human lysine acetyl transferase CBP/p300; developed from a series of 5-isoxazolyl-benzimidazoles. Our starting point was a fragment hit; which was optimized into a more potent and selective lead using parallel synthesis employing Suzuki couplings; benzimidazole-forming reactions; and reductive aminations. The selectivity of the lead compound against other bromodomain family members was investigated using a thermal stability assay; which revealed some inhibition of the structurally related BET family members. To address the BET selectivity issue; X-ray crystal structures of the lead compound bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compounds. The crystal structures obtained revealed two distinct binding modes. By varying the aryl substitution pattern and developing conformationally constrained analogues; selectivity for CBP over BRD4(1) was increased. The optimized compound is highly potent (K d = 21 nM) and selective; displaying 40-fold selectivity over BRD4(1). Cellular activity was demonstrated using fluorescence recovery after photo-bleaching (FRAP) and a p53 reporter assay. The optimized compounds are cell-active and have nanomolar affinity for CBP/p300; therefore; they should be useful in studies investigating the biological roles of CBP and p300 and to validate the CBP and p300 bromodomains as therapeutic targets. © 2014 American Chemical Society;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Journal article (JA)
引用
收藏
相关论文
共 50 条
  • [1] Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
    Hay, Duncan A.
    Fedorov, Oleg
    Martin, Sarah
    Singleton, Dean C.
    Tallant, Cynthia
    Wells, Christopher
    Picaud, Sarah
    Philpott, Martin
    Monteiro, Octovia P.
    Rogers, Catherine M.
    Conway, Stuart J.
    Rooney, Timothy P. C.
    Tumber, Anthony
    Yapp, Clarence
    Filippakopoulos, Panagis
    Bunnage, Mark E.
    Mueller, Susanne
    Knapp, Stefan
    Schofield, Christopher J.
    Brennan, Paul E.
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2014, 136 (26) : 9308 - 9319
  • [2] Targeting oncogenic enhancer activity with a small-molecule CBP/P300 bromodomain inhibitor
    Raisner, Ryan
    Bainer, Russell
    Chan, Emily
    Garcia, Jesse
    Merchant, Mark
    Gascoigne, Karen
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300
    Lai, Kwong Wah
    Romero, F. Anthony
    Tsui, Vickie
    Beresini, Maureen H.
    Boenig, Gladys de Leon
    Bronner, Sarah M.
    Chen, Kevin
    Chen, Zhongguo
    Choo, Edna F.
    Crawford, Terry D.
    Cyr, Patrick
    Kaufman, Susan
    Li, Yingjie
    Liao, Jiangpeng
    Liu, Wenfeng
    Ly, Justin
    Murray, Jeremy
    Shen, Weichao
    Wai, John
    Wang, Fei
    Zhu, Caicai
    Zhu, Xiaoyu
    Magnuson, Steven
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (01) : 15 - 23
  • [4] Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs
    Katavolos, Paula
    Cain, Gary
    Farman, Cindy
    Romero, F. Anthony
    Magnuson, Steven
    Ly, Justin Q.
    Choo, Edna F.
    Katakam, Anand Kumar
    Andaya, Roxanne
    Maher, Jonathan
    TOXICOLOGIC PATHOLOGY, 2020, 48 (03) : 465 - 480
  • [5] Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
    Picaud, Sarah
    Fedorov, Oleg
    Thanasopoulou, Angeliki
    Leonards, Katharina
    Jones, Katherine
    Meier, Julia
    Olzscha, Heidi
    Monteiro, Octovia
    Martin, Sarah
    Philpott, Martin
    Tumber, Anthony
    Filippakopoulos, Panagis
    Yapp, Clarence
    Wells, Christopher
    Che, Ka Hing
    Bannister, Andrew
    Robson, Samuel
    Kumar, Umesh
    Parr, Nigel
    Lee, Kevin
    Lugo, Dave
    Jeffrey, Philip
    Taylor, Simon
    Vecellio, Matteo L.
    Bountra, Chas
    Brennan, Paul E.
    O'Mahony, Alison
    Velichko, Sharlene
    Mueller, Susanne
    Hay, Duncan
    Daniels, Danette L.
    Urh, Marjeta
    La Thangue, Nicholas B.
    Kouzarides, Tony
    Prinjha, Rab
    Schwaller, Juerg
    Knapp, Stefan
    CANCER RESEARCH, 2015, 75 (23) : 5106 - 5119
  • [6] Discovery of a Potent and Selective Covalent p300/CBP Inhibitor
    Mastracchio, Anthony
    Lai, Chunqiu
    Digiammarino, Enrico
    Ready, Damien B.
    Lasko, Loren M.
    Bromberg, Kenneth D.
    McClellan, William J.
    Montgomery, Debra
    Manaves, Vlasios
    Shaw, Bailin
    Algire, Mikkel
    Patterson, Melanie J.
    Sun, Chaohong C.
    Rosenberg, Saul
    Lai, Albert
    Michaelides, Michael R.
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (05): : 726 - 731
  • [7] p300/CBP and cancer
    Narayanan Gopalakrishna Iyer
    Hilal Özdag
    Carlos Caldas
    Oncogene, 2004, 23 : 4225 - 4231
  • [8] p300/CBP and cancer
    Iyer, NG
    Özdag, H
    Caldas, C
    ONCOGENE, 2004, 23 (24) : 4225 - 4231
  • [9] Small-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response
    Jaschke, Nikolai P.
    Breining, Dorit
    Hofmann, Maura
    Paehlig, Sophie
    Baschant, Ulrike
    Oertel, Reinhard
    Traikov, Sofia
    Grinenko, Tatyana
    Saettini, Francesco
    Biondi, Andrea
    Stylianou, Myrto
    Bringmann, Henrik
    Zhang, Cuiling
    Yoshida, Tomomi M.
    Weidner, Heike
    Poller, Wolfram C.
    Swirski, Filip K.
    Goebel, Andy
    Hofbauer, Lorenz C.
    Rauner, Martina
    Scheiermann, Christoph
    Wang, Andrew
    Rachner, Tilman D.
    IMMUNITY, 2024, 57 (02) : 364 - 378.e9
  • [10] Dual Labeling of the CBP/p300 KIX Domain for 19FNMR Leads to Identification of a New Small-Molecule Binding Site
    Gee, Clifford T.
    Arntson, Keith E.
    Koleski, Edward J.
    Staebell, Rachel Lynn
    Pomerantz, William C. K.
    CHEMBIOCHEM, 2018, 19 (09) : 963 - 969
12345